{"filing":{"accession_number":"0001213900-26-078031","cik":"0001821586","ticker":"MLTX","company_name":"MoonLake Immunotherapeutics","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"ea0298054-8k_moonlake.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390026078031/ea0298054-8k_moonlake.htm"},"events":[{"id":17958,"run_id":16110,"accession_number":"0001213900-26-078031","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The filing discloses the exercise of an underwriter option to purchase an additional 1,500,000 Class A ordinary shares, generating $30.0 million in gross proceeds. This is a dilutive equity issuance that increases share count and raises capital, fitting the definition of a dilutive_issuance. The materiality is clear given the substantial capital raised and shareholder dilution involved.","company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":16623,"accession_number":"0001213900-26-078031","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the exercise of an underwriter option to purchase an additional 1,500,000 Class A ordinary shares, generating $30.0 million in gross proceeds. This is a dilutive equity issuance that increases share count and raises capital, fitting the definition of a dilutive_issuance. The materiality is clear given the substantial capital raised and shareholder dilution involved.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T10:01:36.259648+00:00","company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","filing_date":"2026-07-14"}]}